Back to Journals » OncoTargets and Therapy » Volume 17

Effects of miR-330-3p on Invasion, Migration and EMT of Gastric Cancer Cells by Targeting PRRX1-Mediated Wnt/β-Catenin Signaling Pathway [Retraction]

Authors Ma B, Ma J, Yang Y, He X, Pan X, Wang Z, Qian Y 

Received 3 April 2024

Accepted for publication 3 April 2024

Published 5 April 2024 Volume 2024:17 Pages 299—300

DOI https://doi.org/10.2147/OTT.S472066



Ma B, Ma J, Yang Y, et al. Onco Targets Ther. 2020;13:3411–3423.

At the author’s request, we, the Editors and Publisher of OncoTargets and Therapy, have retracted the following article.

Following publication of the article, concerns were raised about the duplication of images from Figure 1. Specifically,

  • The images shown in Figure 1D show duplicated and unexpected features which indicate the original images may have been altered.

The authors responded to our queries but were unable to provide an explanation for the duplicated images or provide satisfactory data for the study. As verifying the validity of published work is core to the integrity of the scholarly record, the authors requested to retract the article and the Editor and Publisher agreed with this decision.

We have been informed in our decision-making by our editorial policies and COPE guidelines.

The retracted article will remain online to maintain the scholarly record, but it will be digitally watermarked on each page as “Retracted”.


This retraction relates to this paper


Creative Commons License © 2024 The Author(s). This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.